The study will enroll approximately 400 patients. This multicenter trial will be conducted in Brazil. Retrospective data of previous IBD treatments (drug, dose, treatment duration, drug changes), and use of other health resources related with the management of IBD for previous three years will be collected. Prospective data will be collected for a period of 12 months in participants with active disease. UC participants, with no or light disease activity at Day 1 will not continue to 12-month follow up. CD participants, with no or light disease activity at Day 1 but with colonoscopy or calprotectin levels (i.e, calprotectin >200 ug/g) in the previous year suggestive of inadequate control of activity will progress to 12-month follow up.